Clear cell sarcoma of tendons and aponeuroses

A study of 75 patients

Akira Kawai, Ako Hosono, Turrent Robert Nakayama, Akihiko Matsumine, Seiichi Matsumoto, Takafumi Ueda, Hiroyuki Tsuchiya, Yasuo Beppu, Hideo Morioka, Hiroo Yabe

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

BACKGROUND. Clear cell sarcoma (CCS) of tendons and aponeuroses (malignant melanoma of soft parts) is a rare melanocytic soft tissue sarcoma. The objective of this study was to determine the clinical features, prognostic factors, and optimal treatment policy for patients with this rare disease. METHODS. Seventy-five consecutive patients with histologically confirmed CCS who received treatment between 1980 and 2004 were analyzed retrospectively. RESULTS. There were 41 men and 34 women, and the median age was 36 years. Sixty-five tumors were located in the extremities, and 10 tumors were located in the trunk. The median tumor size was 4 cm. Seventy-one patients underwent surgical excision, and 56 patients received chemotherapy. Sixteen patients developed local recurrences, and 52 patients developed metastasis. The overall patient survival rates was 47% at 5 years and 36% at 10 years. Univariate analysis showed that sex (P = .018), tumor size (P = .001), tumor depth (P = .002), TNM classification (P = .001), and surgical margin (P = .042) were significant prognostic factors. Among the 52 patients who presented with localized disease, sex (P = .023), tumor size (P = .002), tumor depth (P = .011), TNM classification (P = .004), and chemotherapy (P = .032) were identified as significant prognostic factors. Multivariate analysis showed that tumor size remained an independent prognostic factor in both groups. CONCLUSIONS. The current results supported the contention that early diagnosis and initial wide excision are essential for a favorable outcome of CCS. The role of chemotherapy for CCS should be investigated further.

Original languageEnglish
Pages (from-to)109-116
Number of pages8
JournalCancer
Volume109
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Clear Cell Sarcoma
Tendons
Neoplasms
Neoplasm Staging
Drug Therapy
Aponeurosis
Rare Diseases
Sarcoma
Early Diagnosis
Multivariate Analysis
Survival Rate
Extremities
Neoplasm Metastasis
Recurrence

Keywords

  • Chemotherapy
  • Clear cell sarcoma
  • Malignant melanoma of soft parts
  • Prognostic factors
  • Tumor size

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kawai, A., Hosono, A., Nakayama, T. R., Matsumine, A., Matsumoto, S., Ueda, T., ... Yabe, H. (2007). Clear cell sarcoma of tendons and aponeuroses: A study of 75 patients. Cancer, 109(1), 109-116. https://doi.org/10.1002/cncr.22380

Clear cell sarcoma of tendons and aponeuroses : A study of 75 patients. / Kawai, Akira; Hosono, Ako; Nakayama, Turrent Robert; Matsumine, Akihiko; Matsumoto, Seiichi; Ueda, Takafumi; Tsuchiya, Hiroyuki; Beppu, Yasuo; Morioka, Hideo; Yabe, Hiroo.

In: Cancer, Vol. 109, No. 1, 01.01.2007, p. 109-116.

Research output: Contribution to journalArticle

Kawai, A, Hosono, A, Nakayama, TR, Matsumine, A, Matsumoto, S, Ueda, T, Tsuchiya, H, Beppu, Y, Morioka, H & Yabe, H 2007, 'Clear cell sarcoma of tendons and aponeuroses: A study of 75 patients', Cancer, vol. 109, no. 1, pp. 109-116. https://doi.org/10.1002/cncr.22380
Kawai A, Hosono A, Nakayama TR, Matsumine A, Matsumoto S, Ueda T et al. Clear cell sarcoma of tendons and aponeuroses: A study of 75 patients. Cancer. 2007 Jan 1;109(1):109-116. https://doi.org/10.1002/cncr.22380
Kawai, Akira ; Hosono, Ako ; Nakayama, Turrent Robert ; Matsumine, Akihiko ; Matsumoto, Seiichi ; Ueda, Takafumi ; Tsuchiya, Hiroyuki ; Beppu, Yasuo ; Morioka, Hideo ; Yabe, Hiroo. / Clear cell sarcoma of tendons and aponeuroses : A study of 75 patients. In: Cancer. 2007 ; Vol. 109, No. 1. pp. 109-116.
@article{534ae5e670034a459dcd6ced60cc18e6,
title = "Clear cell sarcoma of tendons and aponeuroses: A study of 75 patients",
abstract = "BACKGROUND. Clear cell sarcoma (CCS) of tendons and aponeuroses (malignant melanoma of soft parts) is a rare melanocytic soft tissue sarcoma. The objective of this study was to determine the clinical features, prognostic factors, and optimal treatment policy for patients with this rare disease. METHODS. Seventy-five consecutive patients with histologically confirmed CCS who received treatment between 1980 and 2004 were analyzed retrospectively. RESULTS. There were 41 men and 34 women, and the median age was 36 years. Sixty-five tumors were located in the extremities, and 10 tumors were located in the trunk. The median tumor size was 4 cm. Seventy-one patients underwent surgical excision, and 56 patients received chemotherapy. Sixteen patients developed local recurrences, and 52 patients developed metastasis. The overall patient survival rates was 47{\%} at 5 years and 36{\%} at 10 years. Univariate analysis showed that sex (P = .018), tumor size (P = .001), tumor depth (P = .002), TNM classification (P = .001), and surgical margin (P = .042) were significant prognostic factors. Among the 52 patients who presented with localized disease, sex (P = .023), tumor size (P = .002), tumor depth (P = .011), TNM classification (P = .004), and chemotherapy (P = .032) were identified as significant prognostic factors. Multivariate analysis showed that tumor size remained an independent prognostic factor in both groups. CONCLUSIONS. The current results supported the contention that early diagnosis and initial wide excision are essential for a favorable outcome of CCS. The role of chemotherapy for CCS should be investigated further.",
keywords = "Chemotherapy, Clear cell sarcoma, Malignant melanoma of soft parts, Prognostic factors, Tumor size",
author = "Akira Kawai and Ako Hosono and Nakayama, {Turrent Robert} and Akihiko Matsumine and Seiichi Matsumoto and Takafumi Ueda and Hiroyuki Tsuchiya and Yasuo Beppu and Hideo Morioka and Hiroo Yabe",
year = "2007",
month = "1",
day = "1",
doi = "10.1002/cncr.22380",
language = "English",
volume = "109",
pages = "109--116",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Clear cell sarcoma of tendons and aponeuroses

T2 - A study of 75 patients

AU - Kawai, Akira

AU - Hosono, Ako

AU - Nakayama, Turrent Robert

AU - Matsumine, Akihiko

AU - Matsumoto, Seiichi

AU - Ueda, Takafumi

AU - Tsuchiya, Hiroyuki

AU - Beppu, Yasuo

AU - Morioka, Hideo

AU - Yabe, Hiroo

PY - 2007/1/1

Y1 - 2007/1/1

N2 - BACKGROUND. Clear cell sarcoma (CCS) of tendons and aponeuroses (malignant melanoma of soft parts) is a rare melanocytic soft tissue sarcoma. The objective of this study was to determine the clinical features, prognostic factors, and optimal treatment policy for patients with this rare disease. METHODS. Seventy-five consecutive patients with histologically confirmed CCS who received treatment between 1980 and 2004 were analyzed retrospectively. RESULTS. There were 41 men and 34 women, and the median age was 36 years. Sixty-five tumors were located in the extremities, and 10 tumors were located in the trunk. The median tumor size was 4 cm. Seventy-one patients underwent surgical excision, and 56 patients received chemotherapy. Sixteen patients developed local recurrences, and 52 patients developed metastasis. The overall patient survival rates was 47% at 5 years and 36% at 10 years. Univariate analysis showed that sex (P = .018), tumor size (P = .001), tumor depth (P = .002), TNM classification (P = .001), and surgical margin (P = .042) were significant prognostic factors. Among the 52 patients who presented with localized disease, sex (P = .023), tumor size (P = .002), tumor depth (P = .011), TNM classification (P = .004), and chemotherapy (P = .032) were identified as significant prognostic factors. Multivariate analysis showed that tumor size remained an independent prognostic factor in both groups. CONCLUSIONS. The current results supported the contention that early diagnosis and initial wide excision are essential for a favorable outcome of CCS. The role of chemotherapy for CCS should be investigated further.

AB - BACKGROUND. Clear cell sarcoma (CCS) of tendons and aponeuroses (malignant melanoma of soft parts) is a rare melanocytic soft tissue sarcoma. The objective of this study was to determine the clinical features, prognostic factors, and optimal treatment policy for patients with this rare disease. METHODS. Seventy-five consecutive patients with histologically confirmed CCS who received treatment between 1980 and 2004 were analyzed retrospectively. RESULTS. There were 41 men and 34 women, and the median age was 36 years. Sixty-five tumors were located in the extremities, and 10 tumors were located in the trunk. The median tumor size was 4 cm. Seventy-one patients underwent surgical excision, and 56 patients received chemotherapy. Sixteen patients developed local recurrences, and 52 patients developed metastasis. The overall patient survival rates was 47% at 5 years and 36% at 10 years. Univariate analysis showed that sex (P = .018), tumor size (P = .001), tumor depth (P = .002), TNM classification (P = .001), and surgical margin (P = .042) were significant prognostic factors. Among the 52 patients who presented with localized disease, sex (P = .023), tumor size (P = .002), tumor depth (P = .011), TNM classification (P = .004), and chemotherapy (P = .032) were identified as significant prognostic factors. Multivariate analysis showed that tumor size remained an independent prognostic factor in both groups. CONCLUSIONS. The current results supported the contention that early diagnosis and initial wide excision are essential for a favorable outcome of CCS. The role of chemotherapy for CCS should be investigated further.

KW - Chemotherapy

KW - Clear cell sarcoma

KW - Malignant melanoma of soft parts

KW - Prognostic factors

KW - Tumor size

UR - http://www.scopus.com/inward/record.url?scp=33846308162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846308162&partnerID=8YFLogxK

U2 - 10.1002/cncr.22380

DO - 10.1002/cncr.22380

M3 - Article

VL - 109

SP - 109

EP - 116

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -